-
1.发明公开
公开(公告)号：EP3585908A1
公开(公告)日：2020-01-01
申请号：EP18707022.2
申请日：2018-02-22
发明人： WENGNER, Antje, Margret , SIEMEISTER, Gerhard , HÄNDLER, Bernard , GOLFIER, Sven , SCHLICKER, Andreas , LIU, Li
IPC分类号： C12Q1/6886
-
2.发明公开COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER 审中-公开一个IMIDAZOPYRIDAZINDERIVAT组合和一个分裂剂用于癌症的治疗
公开(公告)号：EP3007698A1
公开(公告)日：2016-04-20
申请号：EP14732122.8
申请日：2014-06-11
IPC分类号： A61K31/5025
CPC分类号： A61K31/5025 , A61K31/337 , A61K31/475 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.
-
3.发明公开COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING A MPS-1 KINASE INHIBITOR AND A MITOTIC INHIBITOR 审中-公开KOMBINATIONEN ZUR BEHANDLUNG VON KREBS MIT EINEM MPS-1-KINASEINHIBITOR UND EINEM MITOTISCHEN INHIBITOR
公开(公告)号：EP3007692A1
公开(公告)日：2016-04-20
申请号：EP14734010.3
申请日：2014-06-06
IPC分类号： A61K31/337 , A61K31/437 , A61K31/475 , A61K33/24 , A61P35/00
CPC分类号： A61K31/437 , A61K31/337 , A61K31/475 , A61K33/24 , A61K2300/00
摘要： The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.
摘要翻译： 本发明涉及包含Mps-1激酶抑制剂和有丝分裂抑制剂的组合。 本发明还涉及所述组合用于治疗癌症，特别是胰腺癌，胶质母细胞瘤，卵巢癌，非小细胞肺癌，乳腺癌和/或胃癌的用途。
-
公开(公告)号：EP3781565A1
公开(公告)日：2021-02-24
申请号：EP19720074.4
申请日：2019-04-15
发明人： WORTMANN, Lars , SAUTIER, Brice , EIS, Knut , BRIEM, Hans , BÖHNKE, Niels , VON NUSSBAUM, Franz , HILIG, Roman , BADER, Benjamin , SCHRÖDER, Jens , PETERSEN, Kirstin , LIENAU, Philip , WENGNER, Antje, Margret , MOOSMAYER, Dieter , WANG, Qiuwen
IPC分类号： C07D471/04 , A61K31/519 , A61P35/00
-
公开(公告)号：EP3585365A1
公开(公告)日：2020-01-01
申请号：EP18706514.9
申请日：2018-02-22
IPC分类号： A61K31/00 , A61K31/501 , A61K31/5377 , A61P35/00
-
6.发明公开
公开(公告)号：EP2958920A1
公开(公告)日：2015-12-30
申请号：EP14705330.0
申请日：2014-02-18
发明人： EIS, Knut , PÜHLER, Florian , ZORN, Ludwig , SCHULZE, Volker , SÜLZLE, Detlev , LIENAU, Philip , WENGNER, Antje, Margret , PETERSEN, Kirstin , BÖMER, Ulf
IPC分类号： C07D487/04 , C07D491/04 , A61K31/5025 , A61P35/00 , A61P29/00 , A61P37/00
CPC分类号： A61K31/5025 , A61K9/0019 , A61K9/19 , A61K9/20 , A61K9/48 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D487/04 , C07D491/04 , C07D519/00 , C07F7/1856
摘要： The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): (Ia) (Ib) (Ic) (Id) in which A, Y, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
摘要翻译： 本发明涉及通式（I）：（Ia）（Ib）（Ic）（Id）的酰氨基取代的咪唑并哒嗪化合物，其中A，Y，R 1，R 2，R 3，R 4和n如权利要求 ，制备所述化合物的方法，可用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合，以及所述化合物用于制备用于治疗或预防疾病的药物组合物的用途，特别是 高增殖和/或血管生成障碍，作为唯一的药剂或与其它活性成分组合。
-
公开(公告)号：EP3601267A1
公开(公告)日：2020-02-05
申请号：EP18717840.5
申请日：2018-03-19
发明人： WORTMANN, Lars , SAUTIER, Brice , EIS, Knut , BRIEM, Hans , BÖHNKE, Niels , VON NUSSBAUM, Franz , HILLIG, Roman , BADER, Benjamin , SCHRÖDER, Jens , PETERSEN, Kirstin , LIENAU, Philip , WENGNER, Antje, Margret , MOOSMAYER, Dieter , WANG, Qiuwen , SCHICK, Hans
IPC分类号： C07D403/12 , C07D405/14 , C07D401/12 , C07D403/04 , C07D405/10 , C07D405/12 , C07D409/12 , C07D409/14 , C07D239/94 , C07D417/12 , C07D487/04 , C07D495/04 , A61P35/00 , A61K31/517
-
公开(公告)号：EP3576742A1
公开(公告)日：2019-12-11
申请号：EP18704189.2
申请日：2018-02-01
申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft
发明人： LEWIS, Timothy, A. , WU, Xiaoyun , GREULICH, Heidi , MEYERSON, Matthew , ELLERMANN, Manuel , LIENAU, Philip , EIS, Knut , WENGNER, Antje, Margret , KOPITZ, Charlotte, Christine , LANGE, Martin
IPC分类号： A61K31/501 , C07D413/10 , A61P35/00
-
9.发明公开
公开(公告)号：EP3411037A1
公开(公告)日：2018-12-12
申请号：EP17704195.1
申请日：2017-02-03
申请人： Bayer Pharma Aktiengesellschaft , The Broad Institute, Inc. , Dana Farber Cancer Institute, Inc.
发明人： WENGNER, Antje, Margret , EIS, Knut , LIENAU, Philip , SACK, Ulrike , LANGE, Martin , GREULICH, Heidi , MEYERSON, Matthew , DE WAAL, Luc , SCHENONE, Monica , BURGIN, Alex , LEWIS, Timothy, A. , WU, Xiaoyun
IPC分类号： A61K31/50 , A61K31/5375 , A61K45/00 , G01N33/68 , A61P35/00
CPC分类号： A61K31/50 , A61K31/5375 , A61P35/00 , G01N33/68 , G01N2333/4703 , G01N2333/916 , G01N2800/52
摘要： The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3Ll) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
-
公开(公告)号：EP3004092B1
公开(公告)日：2017-03-22
申请号：EP14727534.1
申请日：2014-06-03
发明人： SCHIROK, Hartmut , SCHULZE, Volker , KOSEMUND, Dirk , BRIEM, Hans , BADER, Benjamin , BÖMER, Ulf , WENGNER, Antje, Margret , SIEMEISTER, Gerhard , LIENAU, Philip
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K31/496 , A61K31/5377 , A61K45/06
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.018 秒)
